ATE395934T1 - Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen - Google Patents

Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen

Info

Publication number
ATE395934T1
ATE395934T1 AT00905742T AT00905742T ATE395934T1 AT E395934 T1 ATE395934 T1 AT E395934T1 AT 00905742 T AT00905742 T AT 00905742T AT 00905742 T AT00905742 T AT 00905742T AT E395934 T1 ATE395934 T1 AT E395934T1
Authority
AT
Austria
Prior art keywords
brain tumor
tumor growth
integrin antagonists
antagonists
inhibiting brain
Prior art date
Application number
AT00905742T
Other languages
English (en)
Inventor
Walter Laug
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26815994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE395934(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of ATE395934T1 publication Critical patent/ATE395934T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT00905742T 1999-02-01 2000-01-26 Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen ATE395934T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11812699P 1999-02-01 1999-02-01
US09/489,391 US6521593B1 (en) 1999-02-01 2000-01-21 Methods for inhibiting brain tumor growth

Publications (1)

Publication Number Publication Date
ATE395934T1 true ATE395934T1 (de) 2008-06-15

Family

ID=26815994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905742T ATE395934T1 (de) 1999-02-01 2000-01-26 Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen

Country Status (21)

Country Link
US (2) US6521593B1 (de)
EP (1) EP1150714B1 (de)
JP (1) JP4708568B2 (de)
KR (1) KR100704139B1 (de)
CN (2) CN1191858C (de)
AT (1) ATE395934T1 (de)
AU (2) AU775064B2 (de)
BR (1) BR0007875A (de)
CA (1) CA2360146C (de)
CZ (1) CZ301480B6 (de)
DE (1) DE60038951D1 (de)
DK (1) DK1150714T3 (de)
ES (1) ES2304942T3 (de)
HU (1) HU230025B1 (de)
MX (1) MXPA01007765A (de)
NO (1) NO329695B1 (de)
PL (1) PL202082B1 (de)
PT (1) PT1150714E (de)
RU (1) RU2377017C2 (de)
SK (1) SK287326B6 (de)
WO (1) WO2000044404A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122635B2 (en) * 1999-01-06 2006-10-17 University Of Southern California Method and composition for angiogenesis inhibition
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
WO2003006893A2 (en) 2001-07-09 2003-01-23 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2005044978A2 (en) * 2003-07-15 2005-05-19 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US7785632B2 (en) * 2003-09-15 2010-08-31 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
CA2622852A1 (en) * 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP2054442A2 (de) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denaturierte collagen-peptide und anwendungen davon
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
ES2535005T3 (es) * 2006-12-22 2015-05-04 Nanopharmaceuticals Llc Formulaciones de nanopartículas y de polímeros para análogos, antagonistas y formulaciones de la hormona tiroidea, y usos de los mismos
CA2697070A1 (en) * 2007-08-24 2009-03-05 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
AU2009331955B2 (en) 2008-12-23 2015-09-24 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
WO2010148007A2 (en) * 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
CA2810746A1 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
CA2856329A1 (en) 2011-11-17 2013-05-23 Nencki Institute Of Experimental Biology Compositions and methods for treating glioma
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
US20170000905A1 (en) * 2015-06-30 2017-01-05 Mousera, Inc Device and method of personalized medicine
WO2017214299A1 (en) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
RU2709215C1 (ru) * 2019-09-12 2019-12-17 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Институт катализа им. Г.К. Борескова Сибирского отделения Российской академии наук" (ИК СО РАН) Способ подавления роста опухолей глиального происхождения
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DK0719859T3 (da) * 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
JP2002515036A (ja) * 1996-05-31 2002-05-21 ザ スクリップス リサーチ インスティテュート α▲下Ｖ▼β▲下５▼媒介血管形成の抑制に有用な方法および組成物
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CZ20002269A3 (cs) * 1998-12-14 2001-01-17 Merck & Co., Inc. Látky antagonizující receptor íntegrinu

Also Published As

Publication number Publication date
CN1660426A (zh) 2005-08-31
RU2005107614A (ru) 2006-08-27
CZ20012793A3 (cs) 2002-03-13
KR100704139B1 (ko) 2007-04-09
CZ301480B6 (cs) 2010-03-17
CA2360146A1 (en) 2000-08-03
AU2737900A (en) 2000-08-18
NO20013750D0 (no) 2001-07-31
CN1355711A (zh) 2002-06-26
EP1150714A2 (de) 2001-11-07
WO2000044404A2 (en) 2000-08-03
HUP0105155A2 (hu) 2002-04-29
US6521593B1 (en) 2003-02-18
US20030157098A1 (en) 2003-08-21
AU775064B2 (en) 2004-07-15
JP2002535375A (ja) 2002-10-22
KR20020001726A (ko) 2002-01-09
DK1150714T3 (da) 2008-08-18
AU2004220756A1 (en) 2004-11-11
NO329695B1 (no) 2010-12-06
HU230025B1 (hu) 2015-05-28
WO2000044404A3 (en) 2000-11-30
AU2004220756B2 (en) 2007-05-10
RU2377017C2 (ru) 2009-12-27
HUP0105155A3 (en) 2004-08-30
PL359602A1 (en) 2004-08-23
PL202082B1 (pl) 2009-05-29
CN1332713C (zh) 2007-08-22
JP4708568B2 (ja) 2011-06-22
ES2304942T3 (es) 2008-11-01
MXPA01007765A (es) 2003-06-04
PT1150714E (pt) 2008-07-30
NO20013750L (no) 2001-09-28
SK287326B6 (sk) 2010-07-07
DE60038951D1 (de) 2008-07-03
EP1150714B1 (de) 2008-05-21
CN1191858C (zh) 2005-03-09
BR0007875A (pt) 2002-02-13
SK10622001A3 (sk) 2002-04-04
CA2360146C (en) 2013-05-21

Similar Documents

Publication Publication Date Title
ATE395934T1 (de) Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen
IL151032A0 (en) Integrin antagonists
ATE418999T1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
ATE253903T1 (de) Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
ATE511861T1 (de) Verfahren zur inaktivierung von mikroorganismen unter verwendung von photosensibilisatoren
DE69928697D1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
ATE374642T1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
ATE494388T1 (de) Neues verfahren zum erschaffen von proteinkinase- inhibitoren
DE69810351D1 (de) Verfahren zur begrenzung des wachstums von mikroorganismen durch verwendung metallhaltiger verbindungen
ATE306932T1 (de) Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
ATE250673T1 (de) Verfahren zur identifizierung metastatischer sequenzen
ATE385503T1 (de) Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
DE1206274T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
ATE294853T1 (de) Verwendung von pit-emulsionen in fermentationsverfahren
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
DE59910945D1 (de) Hemmung von alopezie
DE60328979D1 (de) Androgen-reguliertes pmepa1 gen und verfahren zu seiner verwendung zur hemmung von krebszellwachstum
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
DE50111590D1 (de) Verfahren zur bestimmung der konfluenz einer zellschicht auf porösen biomaterialien
DE602004018121D1 (de) Verwendung von alpha2-adrenorezeptor antagonisten zur behandlung von epilepsie
DE60009077D1 (de) Verfahren zur sulfonierung sowie verhinderung von ablagerungen in reaktorbehältern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1150714

Country of ref document: EP